Recombinant baculovirus vaccine containing multiple M2e and adjuvant LTB induces T cell dependent, cross-clade protection against H5N1 influenza virus in mice

Zhang, Jie; Fan, Huiying; Zhang, Zhen; Zhang, Juan; Zhang, Jiao; Huang, Jianni; Ye, Yu; Liao, Ming

doi:10.1016/j.vaccine.2015.12.039

Cited by 21 publications

(16 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…T-cell-mediated immunity is critical for protective immune responses against natural IAV infection (9-16), but current influenza vaccines elicit poor CD8 ϩ T-cell responses (44). Despite this, few studies have attempted to enhance T-cell immunity in an IAV vaccine, and those that have have focused principally on a single protein component of IAV (45)(46)(47)(48). Much greater efforts have been directed toward the generation of broadly reactive (and broadly neutralizing) antibody responses (49,50).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

A Live Attenuated Influenza Vaccine Elicits Enhanced Heterologous Protection When the Internal Genes of the Vaccine Are Matched to Those of the Challenge Virus

Smith

Rodríguez

Ghouayel

et al. 2020

J Virol

View full text Add to dashboard Cite

Influenza A virus (IAV) causes significant morbidity and mortality, despite the availability of viral vaccines. The efficacy of live attenuated influenza vaccines (LAIVs) has been especially poor in recent years. One potential reason is that the master donor virus (MDV), on which all LAIVs are based, contains either the internal genes of the 1960 A/Ann Arbor/6/60 or the 1957 A/Leningrad/17/57 H2N2 viruses (i.e., they diverge considerably from currently circulating strains). We previously showed that introduction of the temperature-sensitive (ts) residue signature of the AA/60 MDV into a 2009 pandemic A/California/04/09 H1N1 virus (Cal/09) results in only 10-fold in vivo attenuation in mice. We have previously shown that the ts residue signature of the Russian A/Leningrad/17/57 H2N2 LAIV (Len LAIV) more robustly attenuates the prototypical A/Puerto Rico/8/1934 (PR8) H1N1 virus. In this work, we therefore introduced the ts signature from Len LAIV into Cal/09. This new Cal/09 LAIV is ts in vitro, highly attenuated (att) in mice, and protects from a lethal homologous challenge. In addition, when our Cal/09 LAIV with PR8 hemagglutinin and neuraminidase was used to vaccinate mice, it provided enhanced protection against a wild-type Cal/09 challenge relative to a PR8 LAIV with the same attenuating mutations. These findings suggest it may be possible to improve the efficacy of LAIVs by better matching the sequence of the MDV to currently circulating strains. IMPORTANCE Seasonal influenza infection remains a major cause of disease and death, underscoring the need for improved vaccines. Among current influenza vaccines, the live attenuated influenza vaccine (LAIV) is unique in its ability to elicit T-cell immunity to the conserved internal proteins of the virus. Despite this, LAIV has shown limited efficacy in recent years. One possible reason is that the conserved, internal genes of all current LAIVs derive from virus strains that were isolated between 1957 and 1960 and that, as a result, do not resemble currently circulating influenza viruses. We have therefore developed and tested a new LAIV, based on a currently circulating pandemic strain of influenza. Our results show that this new LAIV elicits improved protective immunity compared to a more conventional LAIV.

show abstract

Section: Discussionmentioning

confidence: 99%

“…medium and incubated at 33, 37, or 39°C. At the indicated times (12,24,48, and 72 h p.i. ), TCS were collected, and viral titers were determined by tissue culture infectious dose assay (TCID 50 /ml) as described previously (52).…”

Section: Methodsmentioning

confidence: 99%

A Live Attenuated Influenza Vaccine Elicits Enhanced Heterologous Protection When the Internal Genes of the Vaccine Are Matched to Those of the Challenge Virus

Smith

Rodríguez

Ghouayel

et al. 2020

J Virol

View full text Add to dashboard Cite

show abstract

“…The number of asterisks represents the degree of significance. *P < 0.05, **P < 0.005, and ***P < 0.0005. ns: not significant Although poultry but not mouse represents the natural final host for avian influenza infection, several recent studied evaluated immunogenicity and protective capacity of anti-H5N1 avian influenza vaccines in mice [26][27][28]. In fact, most of the available vaccine strains against avian influenza including the one we used in the present work are generated by reverse genetics [14] on the background of the mouse adapted PR8-H1N1 strain [29] which makes mouse a relevant model for characterizing immune responses induced by such vaccines.…”

Section: Discussionmentioning

confidence: 99%

Immune responses to killed reassorted influenza virus supplemented with natural adjuvants

Razin

Osman

Ali

et al. 2017

Acta Microbiologica et Immunologica Hungarica

View full text Add to dashboard Cite

In this study, we investigated the immunomodulatory effects of a supplemented killed influenza virus (V) by Echinacea purpurea (E) and Nigella sativa (N) extracts and effect of changing the route of immunization from intramuscular (IM) to intraperitoneal (IP). At the 2-, 3- and 4-week post-IM immunizations (WPIMI), the supplemented V with N (VN) induced the most significant IgM response unlike N alone. At the 2 WPIMI, V or VN induced the highest significant IgG levels. At the 2-week post-IP immunization (WPIPI), E and VN induced the most significant IgG levels. Both at the 3 and 4 WPIMI or WPIPI, various treatments induced significant increases in IgG. At the 4 WPIMI, E, V, and V with E (VE) induced significant increases in the CD4+ thymocytes while all IP treatments caused significant increase in their counts. V and VN induced the most significant IM induction of CD8+ thymocytes while their best IP stimulation was induced by N, VE, and VN. At the 4 WPIMI, various treatments caused significant increases in the mesenteric lymph node (MLN) CD4+, CD8+ counts. WPIPI with V or VE caused significant increases in both the CD4+- and CD8+ MLN cells, whereas VN significantly induced CD8+ MLN cells only. WPIPI with various treatments caused significant increases in the B-cell counts and the peak was obtained by VN.

show abstract

“…Accordingly, a baculovirus that both displays and expresses the HA after cell entry elicited more robust immune responses via either administration route . If designed to enhance the mucosal immune response, co-administration of the mucosal adjuvant cholera toxin B subunit (CTB) with the antigen-displaying baculovirus (Prabakaran et al, 2008), or co-display of the heat-labile enterotoxin B subunit (LTB) on the baculovirus surface (Zhang et al, 2016), have proven effective.…”

Section: Examples Of Using Surface-display Strategies In Vaccinationmentioning

confidence: 99%

Baculovirus as Versatile Vectors for Protein Display and Biotechnological Applications

Tsai¹,

Wei²,

Lo³

et al. 2020

Current Issues in Molecular Biology

View full text Add to dashboard Cite

The baculovirus-insect cell system has long been deployed for a variety of applications including for use as biopesticides, for recombinant protein production, transient transgene expression, tissue therapy, and for vaccine production. Apart from the advantage of large-scale heterologous protein production with appropriate eukaryotic post-translational modification, foreign proteins can also be displayed on the viral envelope. This surface-display technology preserves the native multimeric structure of the protein, thereby expanding the clinical and pharmaceutical utility of the baculovirus system. Recombinant baculoviruses displaying major antigens for human or animal viruses can serve as appropriate vaccines. They can also serve as effective diagnostic platforms and various cell-based assay systems. In this review, we discuss progress in applying baculovirus surfacedisplay, including protein display on the envelope, capsid, and occlusion bodies of baculoviruses, as well as on cells. We will also describe strategies for improvement of this biotechnological approach.

show abstract

Recombinant baculovirus vaccine containing multiple M2e and adjuvant LTB induces T cell dependent, cross-clade protection against H5N1 influenza virus in mice

Cited by 21 publications

References 41 publications

A Live Attenuated Influenza Vaccine Elicits Enhanced Heterologous Protection When the Internal Genes of the Vaccine Are Matched to Those of the Challenge Virus

A Live Attenuated Influenza Vaccine Elicits Enhanced Heterologous Protection When the Internal Genes of the Vaccine Are Matched to Those of the Challenge Virus

Immune responses to killed reassorted influenza virus supplemented with natural adjuvants

Baculovirus as Versatile Vectors for Protein Display and Biotechnological Applications

Contact Info

Product

Resources

About